With increasing interest in clinical applications in recent years, gallium-68 (68Ga) has also increased. 68Ga-DOTATATE is used as a radiotracer in positron emission tomography (PET) to detect and evaluate cancer-causing neuroendocrine tumor (NET) cells. A particle accelerator, the cyclotron, is used to generate radioactive isotopes 68Sing extensively.
In a recent study published in the Journal of Nuclear Medicine, a group of researchers based in Canada aimed to develop a complete high-yield integrated solution compliant with Good Manufacturing Practices (GMP). 68Ga-DOTATATE produced by a cyclotron. Clinical innocence and effectiveness were also assessed to determine whether the system could be used as a routine diagnostic tool.
After preparing the target (68Zn) and the radiation process, UCT’s CubeCX was employed as part of 68gakli3 purification process. While target preparation was cost-effective, the dosimetry of 68Ga-DOTATATE can be compared with other PET tracers. Clinical examination confirmed that 68Ga is safe and equal to cyclotron 68Ga produced by a generator.
Citation: Tremblay, Sebastian, et al. “68Ga-DOTATATE prepared from cyclotron produced gallium-68: an integrated solution for safety evaluation and clinical efficacy from the cyclotron vault in neuroendocrine cancer patients.” Journal of Nuclear Medicine (2022).